BREATHDX
Bedside monitoring of infection based on exhaled breath
| Coordinatore | Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 877˙948 € |
| EC contributo | 877˙948 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IAPP |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | coordinator | 201˙834.33 |
| 2 |
PHILIPS ELECTRONICS NEDERLAND B.V.
Organization address
address: Boschdijk 525 contact info |
NL (EINDHOVEN) | participant | 387˙802.94 |
| 3 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 244˙978.80 |
| 4 |
UNIVERSITEIT TWENTE
Organization address
address: DRIENERLOLAAN 5 contact info |
NL (ENSCHEDE) | participant | 43˙332.91 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Molecular analysis of exhaled breath is a new frontier in medical testing with an enormous potential for monitoring respiratory disease. Breath tests are non-invasive and require minimal patient effort. This makes them applicable in a wide range of settings varying from the intensive care unit (ICU) to home. Respiratory infections are the primary cause of death in ICU. More than half of the patients in ICUs worldwide suffer from infections, which lengthen their hospital stays and increase their mortality rate. Timely detection and treatment is important and monitoring infection via breath analysis will have a major impact on healthcare. Electronic nose sensor technology is being developed but there is a need for clinical validation. Also it is not always clear to which specific compounds these sensors are sensitive. In this proposal the focus is on developing a sensor technique, where measurements are obtained and processed at the bedside. This solution will be dedicated to the detection of infection from breath. A synergistic approach is proposed between sensor technology development, clinical validation and complex data interpretation. Knowledge will be exchanged between an industrial partner (Philips, NL) strongly involved in the healthcare and well-being markets, two academic partners (University of Manchester, UK, Academic Medical Centre, NL) that have an impressive track record in breath analysis research in a clinical environment and a research institution (University of Twente, NL) that has promising potential on bedside gas sensor technology that can be tailored to compounds of interest. The inter-sectorial knowledge transfers as defined in this proposal are key to the success of this ambitious goal. The project consists of 6 highly multidisciplinary work packages, which involve sensor development, clinical measurements and validation studies and the development of complex data analysis tools.'